123 related articles for article (PubMed ID: 17484630)
1. Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours.
Lenhard M; Kuemper C; Ditsch N; Diebold J; Stieber P; Friese K; Burges A
Clin Chem Lab Med; 2007; 45(5):657-61. PubMed ID: 17484630
[TBL] [Abstract][Full Text] [Related]
2. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
[TBL] [Abstract][Full Text] [Related]
3. Ovarian Sertoli-Leydig cell tumor with heterologous elements of gastrointestinal type associated with elevated serum alpha-fetoprotein level: an unusual case and literature review.
Horta M; Cunha TM; Marques RC; Félix A
J Radiol Case Rep; 2014 Nov; 8(11):30-41. PubMed ID: 25926909
[TBL] [Abstract][Full Text] [Related]
4. Direct in-vivo detection of atypical hormonal expression of a Sertoli-Leydig cell tumour following stimulation with human chorionic gonadotrophin.
Cohen I; Shapira M; Cuperman S; Goldberger S; Siegal A; Altaras M; Beyth Y
Clin Endocrinol (Oxf); 1993 Oct; 39(4):491-5. PubMed ID: 8287578
[TBL] [Abstract][Full Text] [Related]
5. Sertoli-Leydig cell tumour in a 13-year-old girl.
Böttcher B; Hinney B; Keyser J; Kühnle I; Schweyer S; Emons G
Gynecol Endocrinol; 2011 Feb; 27(2):107-9. PubMed ID: 20586549
[TBL] [Abstract][Full Text] [Related]
6. [Sertoli-Leydig cell tumor of the ovary: case study of a 22-year old woman].
Moussa D; Aziz DA; Niassy DA; Espérence KC; Youssou N; Charles MJ; Alassane D
Pan Afr Med J; 2016; 25():36. PubMed ID: 28154727
[TBL] [Abstract][Full Text] [Related]
7. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
8. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Sertoli-Leydig cell tumours: How typical is their typical presentation?
Melero Cortés LM; Martínez Maestre MÁ; Vieites Pérez-Quintela MB; Gambadauro P
J Obstet Gynaecol; 2017 Jul; 37(5):655-659. PubMed ID: 28485183
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
Lee JH; Chang JH
Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
13. Sertoli-Leydig cell tumor.
Lantzsch T; Stoerer S; Lawrenz K; Buchmann J; Strauss HG; Koelbl H
Arch Gynecol Obstet; 2001 Jan; 264(4):206-8. PubMed ID: 11205710
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features of ovarian Sertoli-Leydig cell tumors.
Zhang HY; Zhu JE; Huang W; Zhu J
Int J Clin Exp Pathol; 2014; 7(10):6956-64. PubMed ID: 25400781
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer.
Wu GP; Ba J; Zhao YJ; Wang EH
Acta Cytol; 2007; 51(4):679-80. PubMed ID: 17718156
[No Abstract] [Full Text] [Related]
16. Sertoli-Leydig cell tumor: a rare ovarian neoplasm. Case report and review of literature.
Sachdeva P; Arora R; Dubey C; Sukhija A; Daga M; Singh DK
Gynecol Endocrinol; 2008 Apr; 24(4):230-4. PubMed ID: 18382911
[TBL] [Abstract][Full Text] [Related]
17. Sertoli Leydig Cell Tumour Initially Misdiagnosed as Polycystic Ovarian Syndrome and Congenital Adrenal Hyperplasia: A Case Report.
Paudyal P; Gurung G; Baral J; Kharel N
JNMA J Nepal Med Assoc; 2020 Nov; 58(231):923-926. PubMed ID: 34506429
[TBL] [Abstract][Full Text] [Related]
18. A case of Sertoli-Leydig cell tumor in a postmenopausal woman.
Caringella A; Loizzi V; Resta L; Ferreri R; Loverro G
Int J Gynecol Cancer; 2006; 16(1):435-8. PubMed ID: 16445673
[TBL] [Abstract][Full Text] [Related]
19. [Ovarian Sertoli-Leydig tumor: A tricky tumor].
Brandone N; Borrione C; Rome A; Maues de Paula A
Ann Pathol; 2018 Apr; 38(2):131-136. PubMed ID: 29398147
[TBL] [Abstract][Full Text] [Related]
20. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
